Source:http://linkedlifedata.com/resource/pubmed/id/15170176
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2004-6-21
|
pubmed:abstractText |
The role of high-dose chemotherapy (HDCT) with PBSCT in the treatment of bone and soft-tissue sarcomas is not established. In total, 27 patients (15 female, median age at TPL 30.6 years (range: 13-59)) were analyzed (Ewing sarcoma family n=8, osteosarcoma n=6, MPNST (malignant peripheral nerve sheath tumor) n=4, synovial sarcoma n=3, liposarcoma n=2, leiomyosarcoma n=2, rhabdomyosarcoma n=1, meningosarcoma n=1). Following chemotherapy and surgery complete remission (CR) (n=9), partial remission (PR) (n=10), stable disease (SD) (n=2) and progressive disease (PD) (n=6) were reached prior HDCT. Different HDCT conditioning regimens were used. One patient died due to cardiac arrest after HDCT. Except hematologic side effects, no WHO grade III-IV complications were observed. Four patients died within 6 months due to PD, disease recurred in another seven patients and led to death, 15 patients are alive with/without disease. The median progression-free survival (PFS) is 12.0 months (range: 0-58), in nine CR patients median PFS is 25.8 months (range: 3-58). Although the role of HDCT in the treatment of sarcomas is not defined, a subgroup of patients who achieved CR before HDCT could benefit from this therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0268-3369
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
37-41
|
pubmed:meshHeading |
pubmed-meshheading:15170176-Adolescent,
pubmed-meshheading:15170176-Adult,
pubmed-meshheading:15170176-Antineoplastic Agents,
pubmed-meshheading:15170176-Bone Neoplasms,
pubmed-meshheading:15170176-Female,
pubmed-meshheading:15170176-Humans,
pubmed-meshheading:15170176-Male,
pubmed-meshheading:15170176-Middle Aged,
pubmed-meshheading:15170176-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:15170176-Remission Induction,
pubmed-meshheading:15170176-Retrospective Studies,
pubmed-meshheading:15170176-Sarcoma,
pubmed-meshheading:15170176-Survival Analysis,
pubmed-meshheading:15170176-Transplantation, Autologous,
pubmed-meshheading:15170176-Treatment Outcome
|
pubmed:year |
2004
|
pubmed:articleTitle |
High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas.
|
pubmed:affiliation |
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. Bernd_Kasper@med.uni-heidelberg.de
|
pubmed:publicationType |
Journal Article
|